Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

Cancer Cell

Volumn 13, Issue 2, 2008, Pages 91-104

  Iorns, Elizabeth ^a   Turner, Nicholas C ^a   Elliott, Richard ^a   Syed, Nelofer ^a   Garrone, Ornella ^b   Gasco, Milena ^b   Tutt, Andrew N J ^a,c   Crook, Tim ^a   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

CELLCYCLE

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE 10 GENE; DRUG SENSITIVITY; GENE; GENETIC TRANSCRIPTION; HORMONAL THERAPY; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; SCREENING;

EID: 38549141939     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.01.001     Document Type: Article

References (33)

1. Altucci L., Addeo R., Cicatiello L., Dauvois S., Parker M.G., Truss M., Beato M., Sica V., Bresciani F., and Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12 (1996) 2315-2324
2. Anderson H., Bulun S., Smith I., and Dowsett M. Predictors of response to aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 106 (2007) 49-54
3. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., Sahmoud T., and The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
4. Cariou S., Donovan J.C., Flanagan W.M., Milic A., Bhattacharya N., and Slingerland J.M. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 9042-9046
5. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2 (2003) 296-313
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351 (1998) 1451-1467
7. Echeverri C.J., Beachy P.A., Baum B., Boutros M., Buchholz F., Chanda S.K., Downward J., Ellenberg J., Fraser A.G., Hacohen N., et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods 3 (2006) 777-779
8. El-Ashry D., Miller D.L., Kharbanda S., Lippman M.E., and Kern F.G. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15 (1997) 423-435
9. Gee J.M., Robertson J.F., Ellis I.O., and Nicholson R.I. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95 (2001) 247-254
10. Iorns E., Lord C.J., Turner N., and Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat. Rev. Drug Discov. 6 (2007) 556-568
11. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12 (2006) 1197-1205
12. Jakowlew S.B., Breathnach R., Jeltsch J.M., Masiakowski P., and Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res. 12 (1984) 2861-2878
13. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., Meijer-van Gelder M.E., Sieuwerts A.M., Portengen H., Dorssers L.C., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23 (2005) 732-740
14. Jones S.E. A new estrogen receptor antagonist-An overview of available data. Breast Cancer Res. Treat. 75 (2002) S19-S21
15. Jordan V.C. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat. 36 (1995) 267-285
16. Kasten M., and Giordano A. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 20 (2001) 1832-1838
17. Kenny F.S., Hui R., Musgrove E.A., Gee J.M., Blamey R.W., Nicholson R.I., Sutherland R.L., and Robertson J.F. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5 (1999) 2069-2076
18. Lavoie J.N., L'Allemain G., Brunet A., Muller R., and Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271 (1996) 20608-20616
19. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25 (2007) 1239-1246
20. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: The second decade. Cell 83 (1995) 835-839
21. Musgrove E.A., and Sutherland R.L. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5 (1994) 381-389
22. Myers E., Hill A.D., Kelly G., McDermott E.W., O'Higgins N.J., Buggy Y., and Young L.S. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin. Cancer Res. 11 (2005) 2111-2122
23. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., and El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol. Endocrinol. 15 (2001) 1344-1359
24. Pérez-Tenorio G., Stål O., and the Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86 (2002) 540-545
25. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura S., Lawrence Jr. J., MacMahon L.P., Yue W., and Berstein L. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J. Steroid Biochem. Mol. Biol. 95 (2005) 155-165
26. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
27. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 (2004) 926-935
28. Smith P., Nicholson L.J., Syed N., Payne A., Hiller L., Garrone O., Occelli M., Gasco M., and Crook T. Epigenetic inactivation implies independent tumour suppressor functions for IGFBP-rP1 and the related IGFBPL1 in breast cancer. Clin. Cancer Res. 15 (2007) 4061-4068
29. Svensson S., Jirström K., Rydén L., Roos G., Emdin S., Ostrowski M.C., and Landberg G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24 (2005) 4370-4379
30. Swanton C., Marani M., Pardo O., Warne P.H., Kelly G., Sahai E., Elustondo F., Chang J., Temple J., Ahmed A.A., et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11 (2007) 498-512
31. Whitehurst A.W., Bodemann B.O., Cardenas J., Ferguson D., Girard L., Peyton M., Minna J.D., Michnoff C., Hao W., Roth M.G., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446 (2007) 815-819
32. Wilcken N.R., Prall O.W., Musgrove E.A., and Sutherland R.L. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 3 (1997) 849-854
33. Wingender E., Dietze P., Karas H., and Knuppel R. TRANSFAC: A database on transcription factors and their DNA binding sites. Nucleic Acids Res. 24 (1996) 238-241